Advanced International Breast Cancer Course (AIBCC)

Teaching method

The need to modify format and time has turned Aibcc 2020 into a larger project that allows a better fruition and involvement.

Two sessions are planned:

• Async distance learning with main lectures that will be on-line from September 25th, 2020
• 2 live webinars (October 8^th and 9^th) organized with Q&A and presentation of clinical cases.

Aims

Mortality from breast cancer is declining in most countries thanks to effective screening programs, early diagnosis, molecular characterization of the different subtypes and biology-driven treatments. A multidisciplinary management of breast cancer patients is therefore the key to success and a breast multidisciplinary team should include - besides the “classic” clinical specialties - pathologists, molecular biologists and geneticists. Furthermore, the availability of multiple diagnostic and therapeutic choices, the increasing costs of new technologies and drugs and the issue of sustainability represent a new challenge for socially-responsible clinicians.

With this goal in mind, the Programme includes lectures on molecular characterization, updated treatments of early and advanced disease, management of difficult cases and hereditary syndromes and issues of sustainability and drug access across countries.

Clinical case discussions and debates are planned to allow a continuous and fruitful exchange of experiences and opinions between speakers and participants.

In order to reward scientific excellence and to foster international cooperation, the International Scientific Committee of the 16th AIBCC will award the 10th International Prize for Breast Cancer Research to a scientist who has published a breakthrough paper in the previous year. We also welcome the presentation of posters from participants and the best poster will be awarded during the Award Ceremony.

The Conference is addressed to medical oncologists, pathologists, breast surgeons, radiation oncologists and basic scientists who will have the opportunity to interact with breast cancer leaders and exchange experiences in a friendly atmosphere.

Addressed to

Gynaecologists and obstetrics, medical oncologists, pathologists, radiologists, radiation oncologists, surgeons. Biologists, pharmacists, and nurses.

CME

Based on Italian regulations, Accademia Nazionale di Medicina (provider n. 31) will assign to the activity CME:

• 31-299246 - Async Distance Learning: 9 CME points
• 31-299251 - Live webinar: 6 CME points

Training objective: professional and technical content (knowledge and skills) specific to each profession, specialisation and highly specialised activity. Rare disease.

The credit certification is subject to:

• Professions/specializations should correspond to those which have been accredited for CME
• attendance at the 100% of the async distance learning and webinar live on the platform https://fad.accmed.org
• the completion of the Meeting evaluation online form available at the end of each CME activity
• completion of the final questionnaire (at least 75% of correct answers) at the end of each CME activity

We would like to remind you to participants that only 1/3 of CME credits can come from a sponsorship.

Official Language

The official language of the Meeting is English. No simultaneous translation will be provided.

University of Padua award for advances in breast cancer 2020

The Scientific Committee will select young researchers (< 40 years from any country) who have published in an international peer-reviewed journal, as the principal author, a manuscript reporting important clinical or biological advances in breast cancer.

Free admission is available for a few people “under 40”. Registration forms will be accepted on a first-come, first-served basis unitil spaces are filled. The Organization Secretariat will confirm the registration by email.

Async Distance Learning

Virtual session I: Evolution in cancer prevention and diagnosis

1. Beyond BRCA1/2: Management of women with other predisposition gene mutations
   Claudine Isaacs

2. Tumor infiltrating lymphocytes in breast cancer: role in clinical practice
   Maria Vittoria Dieci

3. Clinical impact of genomics for HER2+ and TNBC
   Aleix Prat

4. New biomarkers ready for prime time (PDL1, PI3K, BRCA, AR etc)
   Giuseppe Viale

Virtual session II: locoregional treatment, life after BC

• Is it safe to avoid axillary node dissection in SN+ patients?
  Elefterios Mamounas

• PMRT after immediate breast reconstruction: the way forward
  Philip Poortmans

• Hormone replacement therapy after BC treatment
  Fedro Peccatori

• Bone Health
  Ingo Diel

• Follow up: how, who, why
  Jacek Jassem

Virtual session III: Systemic treatment for EBC

• How to identify HR+ who are likely to benefit from adjuvant chemotherapy
  Carlo Tondini

• Risk adapted endocrine therapy for HR+ BC (from 5 y tamoxifen to 10 years or more AI)
  Sibylle Loibl

• Neoadjuvant therapy for HER2+ disease: new data, new standard?
  Valentina Guarneri

• Is immunotherapy ready for prime time for early TNBC?
  Hope Rugo

• Post-Neoadjuvant treatments: achievements and opportunities
  Pier Franco Conte

• CDK4/6 inhibitors for early breast cancer
  Gabriel N. Hortobagyi

Virtual Session IV: Advanced Breast Cancer

• Biomarker driven treatment sequencing for HR+ ABC: attempt to reconcile science and label indications
  Stephen Johnston

• HER2+ disease: integrating the drug tsunami
  Sandra Swain

• TNBC: challenges and opportunities
  Miguel Martin

• New promising drugs for advanced breast cancer
  Giuseppe Curigliano

Virtual Session V: Affordability of Breast Cancer Costs and Equity in Access

• The US system: lights and shadows
  Thomas Buchholz

• Reimbursement process in Italy
  Francesco Perrone

• Real World Evidence in Oncology: Opportunities and Pitfalls
  Paolo Bruzzi

• The wave of biosimilars
  Hope Rugo

• The EBCC 2020 Manifesto: how to translate this to clinical reality
  Philip Poortmans

Live Webinar

Thursday, October 8^th

03.50 PM (CET)

On-line registration of participants

04.00 PM (CET)

Introduction to the Conference
Pier Franco Conte, Gabriel N. Hortobagyi, Valentina Guarneri, Philip Poortmans

04.15 PM (CET)

Q&A live virtual session on pre-recorded lectures of session I
Evolution in cancer prevention and diagnosis
Chairmen: Pier Franco Conte, Valentina Guarneri

The authors of the lectures will be connected. Moderators will pose 2-3 questions selected from those arrived in the days before through the virtual platform.

Beyond BRCA1/2: Management of women with other predisposition gene mutations
Claudine Isaacs

Tumor infiltrating lymphocytes in breast cancer: role in clinical practice
Maria Vittoria Dieci

Clinical impact of genomics for HER2+ and TNBC
Aleix Prat

New biomarkers ready for prime time (PDL1, PI3K, BRCA, AR etc)
Giuseppe Viale

04.45 PM (CET)

Q&A live virtual session on pre-recorded lectures of session II
Locoregional treatment, life after BC
Chairmen: Pier Franco Conte, Valentina Guarneri

The authors of the lectures will be connected. Moderators will pose 2-3 questions selected from those arrived in the days before through the virtual platform.

Is it safe to avoid axillary node dissection in SN+ patients?
Elefterios Mamounas

PMRT after immediate breast reconstruction: the way forward
Philip Poortmans

Hormone replacement therapy after BC treatment
Fedro Peccatori

Bone Health
Ingo Diel

Follow up: how, who, why
Jacek Jassem

05.15 PM (CET)

Clinical Case Discussion

• Clinical case: sentinel node biopsy before/after primary systemic therapy
  Presenter: Tania Saibene
  Discussant: Elefterios Mamounas
• Clinical case: radiation therapy after primary systemic therapy treatment
  Presenter: Cristina Falci
  Discussant: Philip Poortmans
• Clinical case: pathologic complete response after CT+trastuzumab and pertuzumab?
  Presenter: Federica Miglietta
  Discussant. Sandra Swain
• Clinical case: young patients with TNBC and BRCA+ (discussion on platinum salts, ovarian stimulation for fertility issues, contralateral surgery)
  Presenter: Gaia Griguolo
  Discussant: Hesham Ahmed Gaballah Elghazaly

06.15 PM (CET)

Proclamation of the best poster

06.30 PM (CET)

Announcement of the winner of UNIPD award that will be handed over in 2021

06.50 PM (CET)

Adjourn

Friday, October 9^th

04.00 PM (CET)

Introduction
Pier Franco Conte, Gabriel N. Hortobagyi, Valentina Guarneri, Philip Poortmans

04.15 PM (CET)

Q&A live virtual session on pre-recorded lectures of session III
Systemic treatment for EBC
Chairmen: Pier Franco Conte, Valentina Guarneri

The authors of the lectures will be connected. Moderators will pose 2-3 questions selected from those arrived in the days before through the virtual platform.

How to identify HR+ who are likely to benefit from adjuvant chemotherapy
Carlo Tondini

Risk adapted endocrine therapy for HR+ BC (from 5 y tamoxifen to 10 years or more AI)
Sibylle Loibl

Neoadjuvant therapy for HER2+ disease: new data, new standard?
Valentina Guarneri

Is immunotherapy ready for prime time for eTNBC?
Hope Rugo

Post-Neoadjuvant treatments: achievements and opportunities
Pier Franco Conte

CDK4/6 inhibitors for early breast cancer
Gabriel N. Hortobagyi

04.45 PM (CET)

Q&A live virtual session on pre-recorded lectures of session IV
Advanced Breast Cancer
Chairmen: Pier Franco Conte, Valentina Guarneri

The authors of the lectures will be connected. Moderators will pose 2-3 questions selected from those arrived in the days before through the virtual platform.

Biomarker driven treatment sequencing for HR+ ABC: attempt to reconcile science and label indications
Stephen Johnston

HER2+ disease: integrating the drug tsunami
Sandra Swain

TNBC: challenges and opportunities
Miguel Martin

New promising drugs for advanced breast cancer
Giuseppe Curigliano

05.15 PM (CET)

Q&A live virtual session on pre-recorded lectures of session V
Affordability of Breast Cancer Costs And Equity In Access
Chairmen: Pier Franco Conte, Valentina Guarneri

The authors of the lectures will be connected. Moderators will pose 2-3 questions selected from those arrived in the days before through the virtual platform.

The US system: lights and shadows
Thomas Buchholz

Reimbursment process in Italy
Francesco Perrone

Real World Evidence in Oncology: Opportunities and Pitfalls
Paolo Bruzzi

The wave of biosimilars
Hope Rugo

The EBCC 2020 Manifesto: how to translate this to clinical reality
Philip Poortmans

05.45 PM (CET)

Clinical Case Discussion

• Clinical case: molecular tumor board and liquid biopsy
  Presenter: Giacomo Pelizzari
  Discussant: Hope Rugo
• Clinical case: oligometastatic disease
  Presenter: Luisa Carbognin
  Discussant: Gabriel N. Hortobagyi
• Clinical case: slowly progressive disease
  Presenter Carlo A. Giorgi
  Discussant P. Franco Conte

06.15 PM (CET)

Conclusions